The Manufacturers Life Insurance Company Invests $1.04 Million in ADMA Biologics Inc $ADMA

The Manufacturers Life Insurance Company bought a new position in ADMA Biologics Inc (NASDAQ:ADMA) during the second quarter, HoldingsChannel reports. The firm bought 124,383 shares of the biotechnology company’s stock, valued at approximately $1,041,000.

Several other hedge funds have also bought and sold shares of ADMA. BlackRock Inc. bought a new stake in ADMA Biologics during the 2nd quarter valued at $321,037,000. State Street Corp lifted its stake in shares of ADMA Biologics by 0.3% in the fourth quarter. State Street Corp now owns 13,597,259 shares of the biotechnology company’s stock valued at $248,014,000 after buying an additional 35,614 shares in the last quarter. Sachem Head Capital Management LP grew its holdings in shares of ADMA Biologics by 27.0% during the fourth quarter. Sachem Head Capital Management LP now owns 11,375,000 shares of the biotechnology company’s stock valued at $207,480,000 after buying an additional 2,415,000 shares during the last quarter. Westfield Capital Management Co. LP grew its holdings in shares of ADMA Biologics by 36.9% during the fourth quarter. Westfield Capital Management Co. LP now owns 6,992,907 shares of the biotechnology company’s stock valued at $127,551,000 after buying an additional 1,886,105 shares during the last quarter. Finally, Capital Research Global Investors increased its position in shares of ADMA Biologics by 104.0% during the fourth quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company’s stock worth $121,067,000 after acquiring an additional 3,383,559 shares in the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on ADMA. Weiss Ratings restated a “hold (c)” rating on shares of ADMA Biologics in a report on Thursday, June 18th. Mizuho cut their price target on ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating for the company in a research note on Wednesday, July 15th. Zacks Research raised ADMA Biologics from a “strong sell” rating to a “hold” rating in a report on Wednesday. Finally, Raymond James Financial assumed coverage on ADMA Biologics in a research note on Wednesday, June 10th. They issued an “outperform” rating and a $21.00 price objective for the company. Three investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $18.67.

ADMA Biologics Stock Performance

NASDAQ ADMA opened at $9.62 on Friday. The company has a fifty day moving average price of $9.15 and a 200-day moving average price of $10.31. The firm has a market cap of $2.15 billion, a price-to-earnings ratio of 13.74 and a beta of 0.78. The company has a debt-to-equity ratio of 0.49, a current ratio of 6.97 and a quick ratio of 3.81. ADMA Biologics Inc has a 1 year low of $7.21 and a 1 year high of $20.46.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 earnings per share for the quarter, hitting the consensus estimate of $0.16. ADMA Biologics had a net margin of 32.98% and a return on equity of 40.17%. The business had revenue of $124.39 million for the quarter, compared to analysts’ expectations of $125.34 million. During the same period in the previous year, the company earned $0.14 earnings per share. The firm’s revenue for the quarter was up 2.0% compared to the same quarter last year. As a group, equities research analysts predict that ADMA Biologics Inc will post 0.78 EPS for the current fiscal year.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.